Insiders Trades
GSK plc Stock: price and insider trades · United Kingdom
9 insiders bought €368k of shares over the last 90 days, the latest filed 22 Sept 2026.
Cluster: 7 buyers in 30 daysGSK plc: what insiders have been doing
GSK plc, classified in the Healthcare & Pharma sector, is a listed company based in London, United Kingdom, founded in 2000. Its insiders report their share dealings to RNS (LSE). From 17 October 2025 to 17 October 2026, the disclosure feed for GSK plc logged 519 filings by 48 insiders.
Both sides are active: 58 purchases worth €1.6M and 41 sales worth €28.6M, from 30 insiders and 18 insiders respectively. The totals exclude 26 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a sale of €2.6M from Tony Wood, disclosed on 17 February 2026. The buyers include 16 board members, 8 chief executives and 6 senior executives.
In the case of 58 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last insider purchase was made public on 22 September 2026, 25 days ago. The median gap between a trade and its publication by RNS (LSE) is 4 days. The legal deadline for notifying a trade is three business days (UK MAR).
For context, the typical company on the same exchange (median of 831 companies) published 6 filings over the same period, against 519 filings here. Over the whole record (from 2023), the tally stands at 167 purchases and 115 sales.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Insider Decl.
1,649
Thresholds
n/a
Buy Volume
€5M
167 ops. · all time
Sell Volume
€61M
115 ops. · all time
Who traded when
BuySaleDiana Conrad8 buys5 sales
Charles Bancroft10 buys
Elizabeth (Liz) McKee Anderson10 buys
James Ford3 buys7 sales
Dr Anne Beal9 buys
Dr Hal Dietz9 buys
+33 other insiders
Analyst consensus: bullish or bearish?
Analysts rate GSK plc Hold (neutral), based on 21 analysts. Average price target: £21.73.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,909 of 24,147 companies
75.8
score / 100
Value72
Quality80
FCF yld6.4%
Earn yld7.6%
EV/EBITDA8.9x
ROE33%
Gross mgn72%
Net mgn17%
Debt/EBITDA1.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
£18.69
Analyst consensus
21 analystsHold
£14.55Target £21.73(+16%)£30.10
Income statement
Revenue£32.7B
Gross profit£23.7B72% margin
EBITDA£10.4B32% margin
Net income£5.7B14.5% margin
Valuation
PER (trailing)16.2x
PER (forward)981.6x
P/Book424.3x
Beta0.28
Balance sheet & cash
Market cap£74.9B
Total debt£17.7B
Free Cash Flow£4.8B
Debt / Equity106%
Profitability & ownership
ROE33.4%
ROA10.0%
% insiders1.7%
% institutions49.0%
Last declaration on 15 October 2026
Declarations1,649 total
326.441 shares@ US$46.94820.1% of flowNew York Stock Exchange (XNYS)ISIN US37733W2044FCA-NSM:baa19e81-6ddf-4ae1-9442-185ca6b9eeb5-0
351.842 shares@ US$46.94820.3% of flowNew York Stock Exchange (XNYS)ISIN US37733W2044FCA-NSM:baa19e81-6ddf-4ae1-9442-185ca6b9eeb5-1
724.875 shares@ US$46.94820.2% of flowNew York Stock Exchange (XNYS)ISIN US37733W2044FCA-NSM:baa19e81-6ddf-4ae1-9442-185ca6b9eeb5-2
783 shares@ £17.3550.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-2
364 shares@ US$46.540.1% of flowNew York Stock Exchange (XNYS)ISIN US37733W2044FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-3
660 shares@ £17.3550.4% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-6
894 shares@ £17.3550.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-4
2,409.639 shares@ £17.3550.3% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-10
1,413 shares@ £17.3550.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-0
1,863 shares@ £17.3550.2% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-1
1,103 shares@ £17.3550.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-5
987 shares@ £17.3550.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-7
179.308 shares@ US$46.540.1% of flowNew York Stock Exchange (XNYS)ISIN US37733W2044FCA-NSM:f33c09b7-347c-4b6a-8bf5-00d11a11d918-9
6,532.657 shares@ £17.59040.7% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-6
2,999.067 shares@ £17.59040.3% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-7
2,707.449 shares@ £17.59041.7% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-8
1.4 shares@ £17.59290.0% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-5
1,204.461 shares@ £17.59040.1% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-9
23.331 shares@ £17.59030.0% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-0
297.818 shares@ £17.59040.6% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-1
1.1 shares@ £17.59090.0% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-2
2,014.345 shares@ £17.59040.2% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-3
246.181 shares@ £17.59040.4% of flowLondon Stock Exchange (XLON)ISIN GB00BN7SWP63FCA-NSM:fe129b5b-39a4-4da0-bd8a-e8ab0eeb5493-4
25 of 1649 declarations
About GSK plc
GSK plc is a major global biopharmaceutical group listed on the London Stock Exchange (FTSE 100/250/AIM) and domiciled in the United Kingdom. The company traces its roots to the long history of GlaxoSmithKline, but in recent years it has been reshaped into a more focused biopharma business following the separation of its consumer healthcare arm. GSK is headquartered in London and now reports under two operating segments: Commercial Operations and Total R&D. Commercial Operations is further organised into three product groups: Vaccines, Specialty Medicines and General Medicines. This structure highlights a business model centred on scientific innovation, intellectual property protection and the extension of the commercial life of key therapies.
From a competitive standpoint, GSK is one of the leading players in vaccines and in several specialist therapeutic areas. Its portfolio is particularly strong in respiratory diseases, immunology, oncology and HIV. The group combines a broad commercial base with a differentiated product mix, underpinned by substantial research and development capabilities and an international manufacturing footprint. In 2024, the vast majority of turnover was generated outside the UK, with the United States representing the largest market, followed by the rest of the world and Europe, underscoring GSK’s status as a geographically diversified global healthcare company.
Read moreShow less
In terms of products and services, GSK sells vaccines, specialty medicines and general medicines. Its strategy is increasingly shaped by pipeline innovation, targeted acquisitions and disciplined capital allocation. Recent developments reinforce this direction: the completion of the acquisition of 35Pharma Inc. in 2025, continued interest in selective external growth opportunities, an agreement with the U.S. government aimed at lowering prices and broadening access to respiratory medicines, and a major planned investment in U.S. R&D and manufacturing infrastructure. The company’s 2025 performance updates also pointed to strong operating momentum, especially in Specialty Medicines, with double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV.
For investors, GSK offers the profile of a large-cap defensive pharmaceutical company with global cash-generating commercial franchises and growth optionality from pipeline development and bolt-on acquisitions. In the context of the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom, it remains a high-quality healthcare name balancing scale, innovation, and regulatory or competitive risks inherent to the sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
